Dr. Patel on Adjuvant Nivolumab Plus Ipilimumab Regimens in Stage IV Melanoma


In Partnership With:

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.

Sapna Patel, MD, medical oncologist, associate professor, director of the Uveal Melanoma Program and Melanoma Fellowship Program, The University of Texas MD Anderson Cancer Center, discusses the evaluation of adjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) in stage IV metastatic melanoma with no evidence of disease [NED].

The phase 2 IMMUNED trial (NCT02523313) aims to evaluate the clinical benefit of adjuvant immunotherapy with nivolumab alone or plus ipilimumab as a postsurgical treatment for patients with NED, Patel explains.

The trial randomly assigned patients to receive nivolumab plus placebo or nivolumab plus ipilimumab vs double placebo, Patel continues. The trial demonstrated an improvement in recurrence-free survival in patients who received adjuvant nivolumab plus ipilimumab vs nivolumab and placebo, Patel states.

A 2-year nivolumab and ipilimumab regimen should be considered for patients who have no evidence of disease after resection or receive radiation for their lesion within 8 weeks of showing no evidence of disease, Patel explains. Moreover, adjuvant nivolumab/ipilimumab should also be considered for patients with BRAF-mutated disease, Patel concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD